DIANT® offers innovators and CDMOs turnkey nanoparticle / LNP manufacturing solutions and R&D services that increase speed to market and reduce risk.
PreciGenome offers high-performance Life Science Instrument & Solutions. We offer lipid nanoparticle LNP synthesis systems, PCR machines & assay, and microfluidic based systems include single-cell platform, cell perfusion system & droplet system, etc. Pr
LNP组成 脂质纳米颗粒(Lipid Nanoparticle,LNP) 是目前主流的载体递送方式,现阶段主要的mRNA疫苗都使用的是此项技术。LNP是一种多组分系统,通常由可电离脂质 (lonizable lipid) 、辅助脂质(Helper lipid) 、胆固醇 (cholesterol) 和聚乙二醇修饰脂质 (PEG-lipid) 组成,它们分工合作,将mRNA包裹在核中以避免降解,帮助...
LipoDrive™ Lipid-based Drug Delivery Platform MORE Functional Liposome Development Liposomal Formulation Development Liposome Analysis & Characterization Lipid Nanoparticle (LNP) Development Liposome Manufacturing Custom Lipid Synthesis About Us As a pioneer with more than ten years of experience in liposom...
events resources careers working at wuxi tides job openings contact us resources lipid nanoparticle (lnp) platform 2024-04-12 prev previous article next article next prev previous next next connect with us about us facilities leadership quality compliance esg service & solution overview services & ...
Lipid Nanoparticle Portfolio Precision NanoSystems enables the world’s leading drug developers to create genomic medicines by offering NanoAssemblr® instruments, ionizable lipids, off-the-shelf reagents, and BioPharma services. Our lipid nanoparticle (LNP) portfolio provides access to off-the-shelf ki...
with a specialization in complex biological products, specifically lipid nanoparticle, liposomal, and PEGylated formulations. In addition, we can customize a pharmaceutical manufacturing process to your exact specifications, offering aseptic product manufacturing in a closed system as well as end-point steri...
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivoLipid nanoparticleBCR-ABLRNAiChronic myeloid leukemiaEfficient and safe delivery of siRNA in vivo is the biggest roadblock to clinical translation of RNA interference (RNAi)-based therapeutics. To date, lipid nanoparticles...
Development of an extended action fostemsavir lipid nanoparticle Farhana Islam Srijanee Das Bhavesh D. Kevadiya Communications Biology(2024) Continuous and size-control synthesis of lipopolyplex nanoparticles enabled by controlled micromixing performance for mRNA delivery ...
LNP专利,mRNA制药产业的痛点 | 江湖 不久前,国际知名mRNA药物巨头Moderna在对Arbutus主动发起的LNP(脂质纳米粒,Lipid Nanoparticle)专利挑战中再度败诉。法院仍认定Arbutus的“435专利部分有效”、“069专利完全有效”。 这一判决结果公布后,Moderna股价直线下挫,而Arbutus盘中股价上涨一度接近翻倍。